LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq:CYTR) today announced the award of a Small Business Innovative Research (SBIR) grant of approximately $222,000 to develop its novel inhibitors to fatty acid synthase for the treatment of type 2 diabetes and obesity. CytRx was awarded the grant by the National Institute of Diabetes and Digestive and Kidney Diseases, a part of the National Institutes of Heath (NIH), based on the Company’s small molecule and structure-based drug design expertise.
